Friday, July 30, 2010 11:41:29 AM
And this from our own Doc. FG:>>As I said Monday, it looks like its time to START buying/adding/getting back in, but leave some powder for adding more if it goes lower. <<
Thanks Doc. I'll call that his one a nibbling "Buy" at current valuations.
>>Also, the base is rising fractionally on strong support but low buying and weak selling. How long that support will last is anyone's guess, but TA suggest we ease higher until Tuesday.<<
Can you tell us what you see for Tuesday?
>>For everyone else it's "for fun" but for the mod it will be cast in stone to be tossed in my face in December.<<
I know this to unfortunatly be true. As I have seen you make predictions in the past and then receive a disproportionate amount of criticism, some with malice, when it should be a 'miss'. This is not right, nor fair. Everyone is equal on their
predictions and should be treated as such by all.
Same is true for a unpopular prediction uttered by perhaps not a popular forum member that comes true. You give the credit where it is due. It's what called 'Fair Play' and it starts with us.
Regards,
-Bunny-
Thanks Doc. I'll call that his one a nibbling "Buy" at current valuations.
>>Also, the base is rising fractionally on strong support but low buying and weak selling. How long that support will last is anyone's guess, but TA suggest we ease higher until Tuesday.<<
Can you tell us what you see for Tuesday?
>>For everyone else it's "for fun" but for the mod it will be cast in stone to be tossed in my face in December.<<
I know this to unfortunatly be true. As I have seen you make predictions in the past and then receive a disproportionate amount of criticism, some with malice, when it should be a 'miss'. This is not right, nor fair. Everyone is equal on their
predictions and should be treated as such by all.
Same is true for a unpopular prediction uttered by perhaps not a popular forum member that comes true. You give the credit where it is due. It's what called 'Fair Play' and it starts with us.
Regards,
-Bunny-
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
